Analysts Update Views on Major Blue-Chip Stocks

Johnson & Johnson (JNJ) drew multiple analyst revisions following its first-quarter 2026 results and recent product developments. On April 20, Guggenheim Partners raised its price target on the shares to $266 while reiterating a Buy rating, citing a reassessment of the Icotyde opportunity after its approval in plaque psoriasis. The firm lifted its unadjusted peak revenue estimate for the drug to $14.9 billion.

During the Q1 2026 earnings call, Vice President of Investor Relations Darren Snellgrove reported worldwide sales of $24.1 billion, net earnings of $5.2 billion, diluted EPS of $2.14 and adjusted diluted EPS of $2.70. CFO Joseph Wolk said the company ended the quarter with about $22 billion in cash and marketable securities and $55 billion in debt, and generated roughly $1.5 billion in free cash flow.

Wolk also told investors that Johnson & Johnson (JNJ) raised its 2026 operational sales outlook to 5.9% to 6.9%, with reported sales now expected to grow 6.5% to 7.5%, and increased earnings guidance to a range of $11.30 to $11.50. He reaffirmed expectations for at least a 50 basis point improvement in adjusted pretax operating margin in 2026 and noted that investment spending will be more heavily weighted to the first half of the year.

Earlier, on April 15, Bank of America (BAC) nudged its price objective on Johnson & Johnson to $254 and kept a Neutral rating, describing the quarter as solid but not thesis-changing. An analyst report from April 20 highlighted that Johnson & Johnson now operates solely through its Innovative Medicine and MedTech divisions after the 2023 divestment of Kenvue, with just over half of revenue generated in the United States.

Analysts also updated views on UnitedHealth Group (UNH) as regulatory visibility and business trends shifted. On April 17, Morgan Stanley (MS) named the stock a Top Pick and maintained an Overweight rating with a $375 price target. The firm pointed to a more favorable Final Medicare Advantage rate and the prospect of a string of cleaner quarters that could lift sentiment and 2027 earnings expectations.

Morgan Stanley (MS)’s $375 target implies about 16% upside from a share price of $323 and is based on applying an 18.3 times multiple to projected 2027 EPS of $20.45. The call followed the Centers for Medicare & Medicaid Services’ decision to finalize the 2027 Medicare Advantage rate at 2.48%, up from 0.09% in the advance notice, easing what had been a key risk to margin recovery.

According to Morgan Stanley (MS), stronger rates give UnitedHealth (UNH) more flexibility to reprice plans, adjust benefits, and manage member mix while targeting around $17.75 or more in adjusted EPS for 2026. The firm sees an improving backdrop shifting the focus toward execution, including benefit design and pricing discipline, and argues that a sub‑86% medical loss ratio in early 2026 would signal that the margin reset is working.

Within Optum Health, Morgan Stanley estimated that Q4 2025 results included roughly a $600 million profit shortfall versus expectations but judged about 70% of that miss to be one‑time in nature rather than structural. Separately, on April 20, Jefferies raised its price target on UnitedHealth to $373, reiterating a Buy rating after revisiting estimates across managed care names.

In U.S. banking, several large institutions saw price target revisions tied to first-quarter updates. Bank of America (BAC)’s Q1 2026 performance led Piper Sandler on April 16 to increase its price target to $59 while maintaining a Neutral stance, and Truist to lift its target to $61 with a Buy rating. Truist’s analyst now assumes 8% net interest income growth for 2026, at the high end of the bank’s updated guidance.

On the earnings call, CFO Borthwick said Bank of America exceeded net interest income expectations in Q1 and has revised its outlook to 6% to 8% NII growth compared with 2025. He highlighted a shift in interest rate expectations from two cuts to none and reaffirmed guidance for more than 200 basis points of positive operating leverage in 2026, with an expected effective tax rate slightly above 20%.

Wells Fargo (WFC) attracted mixed analyst responses after its own Q1 2026 report. On April 15, Morgan Stanley cut its price target to $97 with an Equal Weight rating, reflecting lower net interest income, weaker fee expectations and a higher share count in updated 2026 and 2027 EPS forecasts. Bank of America the same day reduced its target to $95 but kept a Buy rating, citing a 13 basis point quarterly contraction in net interest margin and reduced visibility on earnings.

CEO Charles Scharf told investors that Wells Fargo (WFC)’s diluted EPS rose 15%, revenue increased 6%, loans grew 11% and deposits 7% year over year in Q1 2026. He said the bank had closed its final outstanding consent order in the prior month, for a total of 14 resolved since 2019, and emphasized a renewed focus on accelerating growth and improving returns. The company returned $5.4 billion to shareholders in the quarter, including $4 billion via common share repurchases.

Among consumer and industrial names, analysts adjusted targets ahead of earnings and in response to evolving demand patterns. On April 20, KeyBanc Capital Markets lowered its price target on McDonald’s (MCD) to $345 while reiterating an Overweight rating, flagging a more volatile and uncertain 2026 macro backdrop. The fast‑food chain has rolled out U.S. menu items priced at $3 or less and a $4 breakfast deal to appeal to value‑oriented customers.

In staples, JPMorgan (JPM) on April 17 cut its Procter & Gamble (PG) target to $162 with an Overweight rating as it refreshed forecasts across household and personal care companies. Barclays (BARC.L) on April 14 reduced its Procter & Gamble (PG) target to $146 and kept an Equal Weight rating, highlighting higher input costs and increased caution heading into earnings. Both firms pointed to investor focus on consumer behavior, cost pressures and deal activity.

Analyst attention also turned to 3M (MMM) ahead of its Q1 2026 report. Citigroup (C) on April 13 lowered its price target on the shares to $166 with a Neutral rating as part of a broader industrials preview, while Wells Fargo (WFC) earlier cut its target to $160 but kept an Overweight stance. Citigroup said gradually improving industrial trends should still support solid Q1 results for many sector companies.

Strategic moves continue alongside those rating changes. 3M (MMM) in March announced a $1.95 billion joint venture transaction with Bain Capital to acquire Madison Fire & Rescue, under which 3M will hold a 50.1% stake and contribute its Scott Safety unit while receiving $700 million in cash. Separately, APPLIED Adhesives disclosed on April 16 that it had been accepted into 3M’s Preferred Adhesive Distributor Program, gaining priority supply planning and additional support to serve industrial markets.

In retail, Walmart (WMT) is pushing ahead with brand and store initiatives. On April 15, Reuters reported that the company is redesigning its Great Value private label across nearly 10,000 food and consumables items in its first major refresh in more than a decade. The two‑year rollout will begin with salty snacks and then extend to other categories, with updated packaging designed to provide clearer nutritional information and benefit claims.

Scott Morris, senior vice president of private brands at Walmart (WMT) US, said the Great Value refresh will not change product formulations or pricing. The redesign follows Walmart’s decision to eliminate synthetic dyes from its private‑label foods, including Great Value, by January 2027, and comes as more shoppers gravitate toward lower‑priced store brands. Another recent analysis noted that Walmart is also expanding in‑store offerings from partners such as Pet Honesty and Lucky Energy and enhancing back‑room staging to support same‑day delivery and marketplace logistics.